Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash from Operations (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Cash from Operations data on record, last reported at 6110000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations rose 69.54% year-over-year to 6110000.0; the TTM value through Sep 2025 reached 66140000.0, up 35.3%, while the annual FY2024 figure was 80191000.0, 37.46% up from the prior year.
  • Cash from Operations reached 6110000.0 in Q3 2025 per FBIO's latest filing, up from 27560000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 6110000.0 in Q3 2025 and bottomed at 47844000.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 29346842.11, with a median of 27560000.0 recorded in 2025.
  • Peak YoY movement for Cash from Operations: plummeted 116.06% in 2022, then skyrocketed 69.54% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 38696000.0 in 2021, then decreased by 23.64% to 47844000.0 in 2022, then increased by 26.98% to 34935000.0 in 2023, then soared by 63.05% to 12907000.0 in 2024, then surged by 52.66% to 6110000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 6110000.0 in Q3 2025, 27560000.0 in Q2 2025, and 19563000.0 in Q1 2025.